Trial
NCT01955629
Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals
Condition
Colorectal Cancer Metastatic
Intervention
Aflibercept AVE0005
Why stopped
The study enrollment was prematurely halted due to safety reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-18